If biopsied tissue is not available, 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) can be used for clinical evaluation and quantification of glycolytic phenotype and a surrogate for GLUT1 expression in malignant melanoma (metastases). Here, SLC2A1 is linked to melanoma.